Search

for
Search:

Sort by

Research

30-60 / 1000+ results

Real-World Study of Adverse Events Associated with Gepant Use in Migraine Treatment Based on the VigiAccess and U.S. Food and Drug Administration’s Adverse Event Reporting System Databases

research Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases

25 citations , July 2024 in “Frontiers in Pharmacology”

Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.

research Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017

22 citations , December 2018 in “British Journal of Clinical Pharmacology”

HPV vaccines are generally safe but need further investigation for rare side effects.

The Role of Patient and Drug-Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System

research The Role of Patient‐ and Drug‐Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System

December 2024 in “Journal of Cosmetic Dermatology”

Oral minoxidil rarely causes pericardial effusion, especially at low doses.

A Pharmacovigilance Study of Drug-Reduced Male Semen Quality Based on the Food and Drug Administration Adverse Event Reporting System Database

research A pharmacovigilance study of drug‐reduced male semen quality based on the Food and Drug Administration adverse event reporting system database

June 2024 in “Andrology”

Some drugs can reduce male semen quality.

research Drug-Induced Hair Loss: Analysis of the Food and Drug Administration’s Adverse Events Reporting System Database

July 2024 in “Skin Appendage Disorders”

Certain medications, including some immune drugs, contraceptives, and hair loss treatments, are often linked to hair loss.

Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System

research 0557 Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea (OSA): Results from the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS)

April 2020 in “Sleep”

Some drugs may increase the risk of obstructive sleep apnea, while others like certain biologics might decrease it.

research Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System

7 citations , December 2017 in “Journal of the European Academy of Dermatology and Venereology”

Dutasteride is linked to a higher chance of sexual dysfunction, especially in younger males and the elderly.

research Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database

1 citations , August 2024 in “Expert Opinion on Drug Safety”

Finasteride is most linked to drug-induced erectile dysfunction.

research A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System

2 citations , November 2025 in “Pharmacology Research & Perspectives”

Avacopan may cause unexpected side effects, so early monitoring is important.

research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system

1 citations , November 2025 in “International Journal of Clinical Pharmacy”

Cladribine has known risks and potential new safety concerns, requiring careful monitoring.

research Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.

January 2020 in “PubMed”

Finasteride use is linked to a higher risk of obstructive sleep apnea.

research Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.

January 2020 in “Skinmed”

Finasteride use is linked to a higher risk of obstructive sleep apnea.

Finasteride Is Associated With a Higher Odds of Obstructive Sleep Apnea: Results From the US FDA Adverse Events Reporting System

research 0917 Finasteride is Associated with a Higher Odds of Obstructive Sleep Apnea (OSA): Results from the US FDA Adverse Events Reporting System (FAERS)

1 citations , April 2018 in “Sleep”

Finasteride increases risk of sleep apnea and insomnia.

research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)

March 2026 in “Figshare”

These medications for BPH have known risks and may have new side effects.

research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)

March 2026 in “Figshare”

These medications for BPH have known risks and may have new side effects.

Suicidal Behaviors (Suicidal Ideation, Suicide Attempt and Completed Suicide) in Patients Treated with Finasteride for Hair Loss: Results from the U.S. FDA Adverse Event Reporting System Database

research Suicidal behaviors (suicidal ideation, suicide attempt and completed suicide) in patients treated with finasteride for hair loss: Results from the U.S. FDA Adverse Event Reporting System (FAERS) database

August 2018 in “Journal of The American Academy of Dermatology”

research Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database

3 citations , May 2025 in “Frontiers in Pharmacology”

Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.

research A Gender Hypothesis of sex disparities in adverse drug events

8 citations , November 2023 in “Social Science & Medicine”

Gendered social factors, not just biology, contribute to sex differences in adverse drug events.

research Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases

24 citations , October 2016 in “Oncotarget”

Finasteride has a higher risk of reproductive side effects than minoxidil.

research Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database

2 citations , May 2025 in “Frontiers in Pharmacology”

Aromatase inhibitors can cause skin issues, especially with anastrozole and exemestane, so monitoring is important.

research Machine Learning--Enhanced Pharmacovigilance Assessment of Cardiac Adverse Events Associated With Minoxidil

February 2026

Minoxidil is strongly linked to heart problems, and machine learning can improve drug safety checks.

Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports

research Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports

June 2025 in “Pharmaceuticals”

Finasteride use may increase suicidality risk, especially in young men.

research Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases

2 citations , May 2022 in “International Journal of Impotence Research”

Finasteride may be linked to Peyronie’s disease, but more research is needed.

research Post-Exposure Syndromes as State-Space Trapping: A set-theoretic perspective on PSSD and the post-exposure family.

April 2026 in “Zenodo (CERN European Organization for Nuclear Research)”

Post-exposure syndromes are persistent conditions caused by past exposures, needing unique interventions.

research Post-Exposure Syndromes as State-Space Trapping: A set-theoretic perspective on PSSD and the post-exposure family.

April 2026 in “Zenodo (CERN European Organization for Nuclear Research)”

Post-Exposure Syndromes are persistent conditions caused by past exposures, needing unique interventions.

research Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database

December 2023 in “Expert Opinion on Drug Safety”

Finasteride use is linked to increased reports of cognitive problems, especially in younger people with hair loss.

research Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study

69 citations , July 2015 in “Pharmacotherapy”

Low-dose finasteride may cause lasting sexual dysfunction and suicidal thoughts in young men.

← Previous page Next page →

Search

for
Search:

Research

research Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases

research Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017

research The Role of Patient‐ and Drug‐Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System

research A pharmacovigilance study of drug‐reduced male semen quality based on the Food and Drug Administration adverse event reporting system database

research Drug-Induced Hair Loss: Analysis of the Food and Drug Administration’s Adverse Events Reporting System Database

research 0557 Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea (OSA): Results from the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS)

research Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System

research Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database

research A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System

research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system

research Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.

research Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.

research 0917 Finasteride is Associated with a Higher Odds of Obstructive Sleep Apnea (OSA): Results from the US FDA Adverse Events Reporting System (FAERS)

research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)

research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)

research Suicidal behaviors (suicidal ideation, suicide attempt and completed suicide) in patients treated with finasteride for hair loss: Results from the U.S. FDA Adverse Event Reporting System (FAERS) database

research Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database

research A Gender Hypothesis of sex disparities in adverse drug events

research Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases

research Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database

research Machine Learning--Enhanced Pharmacovigilance Assessment of Cardiac Adverse Events Associated With Minoxidil

research Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports

research Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases

research Post-Exposure Syndromes as State-Space Trapping: A set-theoretic perspective on PSSD and the post-exposure family.

research Post-Exposure Syndromes as State-Space Trapping: A set-theoretic perspective on PSSD and the post-exposure family.

research Controversies: Is Finasteride Safety Data Adequately Reported in Published Trials?

research How routine pharmacovigilance failed to identify finasteride’s persistent sexual side effects

research Implementing patient safety and quality improvement in dermatology. Part 1: Patient safety science

research Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database

research Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study